Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Keith Speights has positions in Pfizer and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Pfizer, and Vertex Pharmaceuticals. The Motley Fool recommends Moderna. The ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA announced it has awarded $20,000 in scholarships to two ...

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

For more information, visit www.merck.com and connect with us on X (formerly Twitter ... N.J., USA This news release of Merck ...

Fundamental company data and analyst estimates provided by FactSet ... Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source ...

Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range ...